louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02175615: Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCT
Official title: PHARMACOLOGICAL PREDICTORS OF SUCCESSFUL CYCLOSPORINE ACUTE GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN CHILDREN UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANT
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute-graft-versus-host Disease
Keywords: CYCLOSPORINE
ACUTE GRAFT VERSUS HOST DISEASE
PROPHYLAXIS
CHILDREN
HAEMATOPOIETIC STEM CELL TRANSPLANT
Lead sponsor: The Hospital for Sick Children
Sponsor class: OTHER
Collaborators: name: C17 Council
First posted: 2014-06-26
Enrollment: 105
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ALLOGENEIC Hematopoietic stem cell transplant recipients

Brief summary: The specific objectives of this study are:

Primary:

1)To determine the relationship between cyclosporine AUC achieved prior to engraftment and severe aGVHD (grade III and IV)

Secondary:

1. To determine the relationship between individual concentration-time points achieved prior to engraftment and severe aGVHD (grade III and IV)
2. To validate the previously developed LSS to determine cyclosporine AUC after IV administration at steady state and
3. To describe the relationship between cyclosporine AUC and individual concentration-time points achieved prior to engraftment and other HSCT outcomes (clinically significant aGVHD (grade II to IV), hypertension, engraftment failure, relapse


Eligibility criteria: Inclusion Criteria:

* less than 18 years of age
* undergoing allogeneic myeloablative HSCT at one of the participating centres and
* scheduled to receive cyclosporine for aGVHD prophylaxis
* minimum patient weight:
* 6.4kg if \< 6 months old or 7.2kg if \> 6 months old

All patients or guardians will provide informed consent or assent as appropriate. Initial contact will be made by a member of the patient's current care team. Consent will be obtained by a co-investigator or the CTSU personnel.

Exclusion Criteria:

-receipt of voriconazole or posaconazole within 14 days of the first cyclosporine dose or at any time until engraftment

Primary outcomes:
measure: Relationship between CSA area-under-the-curve (AUC) prior to ENGRAFTMENT and severe aGVHD
timeFrame: Weekly for 7 weeks or until engraftment and for 100 days after HSCT
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Hospital for Sick Children
state: Ontario
Study officials:
affiliation: SickKids Research Institute
name: Lee Dupuis, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Dupuis LL, Seto W, Teuffel O, Gibson P, Schultz KR, Doyle JD, Gassas A, Egeler RM, Sung L, Schechter T. Prediction of area under the cyclosporine concentration versus time curve in children undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Mar;19(3):418-23. doi: 10.1016/j.bbmt.2012.10.031. Epub 2012 Nov 2.
Clinical trial NCT01636115: Validation of Muscle Strength Testing for Pectoralis Major
Official title: Validation of Muscle Strength Testing for Pectoralis Major
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pectoralis Major
Muscle Strength
Surface EMG
Force Measurement
Lead sponsor: National Science and Technology Council, Taiwan
Sponsor class: OTHER_GOV
First posted: 2012-07-10
Enrollment: 24
Sex: MALE
Minimum age (years): 17
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Students in University.

Brief summary: This study wants to understand which direction of shoulder movement and what posture of shoulder are best for the procedure of muscle strength testing of the muscle pectoralis major(PM). We will use muscle activity signals (sEMG) and force measurement to analyze the contribution of two parts of PM in three different contraction direction with three different shoulder postures.


Eligibility criteria: Inclusion Criteria:

* Young male subjects which could expose the area of anterior chest to paste the sEMG electrodes

Exclusion Criteria:

* Injury and uncomforted one week before the test

Primary outcomes:
measure: sEMG
timeFrame: 6/1/2012
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: I-Shou university
Study officials:
References:
Clinical trial NCT04821115: Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease
Official title: Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peyronie Disease
Penile Diseases
Lead sponsor: Hopital Foch
Sponsor class: OTHER
Collaborators: name: Dornier MedTech Systems
First posted: 2021-03-29
Enrollment: 120
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Investigation of the effect of Low-intensity extracorporeal shockwave therapy (ESWT) for Peyronie's disease (PD) via a single blind, sham-controlled, randomized clinical trial. Investigators will not be blinded to group assignments, but penile curvature will be assessed from coded patient pictures by a blinded assessor.


Eligibility criteria: Inclusion Criteria:

* ≥18 years old male,
* Untreated Peyronie's disease (excepted oral therapy) (wash out: at least 1 month),
* Single axis penile curvature in erection at 20 - 90 degrees at baseline,
* Dorsal or lateral penile plaque,
* Able and willing to perform ESWT self-treatment under supervision,
* Able to understand and complete patient questionnaires,
* Having sign an informed consent form prior to any study specific procedure,
* Being covered by a national health insurance

Exclusion Criteria:

* Congenital penile deformity,
* Hourglass deformity,
* Circumferential plaque,
* Septal or ventral plaque,
* Plaque that cannot be palpated during clinical examination,
* Previous intralesional injection for Peyronie's Disease,
* Severe erectile dysfunction (EHS \< 3),
* Current penile, malignancy,
* Previous penile surgery except for circumcision or condyloma removal,
* Previous pelvic radiation therapy,
* Anti-coagulant medication, except acetylsalicylic acid up to 100mg daily,
* Previous low-intensity focused shockwave therapy on penis,
* Any other condition that would prevent the patient from completing the study, as judged by the principal investigator,
* Being deprived of liberty or under guardianship.

Primary outcomes:
measure: Effect of low intensity ESWT on penile curvature in erection in patients with Peyronie's disease
timeFrame: 15 months
Secondary outcomes:
measure: Assessment of the safety of ESWT on patients with PD: adverse events
timeFrame: 3 months
measure: Assessment of the effect of ESWT on penile pain
timeFrame: 3 months
measure: Assessment of the effect of ESWT on sexual bother
timeFrame: 3 months
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Centre d'Urologie du Polygone
city: Nice
country: France
facility: Hôpital Pasteur 2
city: Suresnes
country: France
facility: Foch hospital
city: Toulouse
country: France
facility: Hôpital Rangueil
Study officials:
affiliation: Hopital Foch
name: Thierry LEBRET, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06603415: Hashimoto's Thyroiditis in Upper Egypt
Official title: Pattern of Hashimoto's Thyroiditis in Upper Egypt
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Hashimoto's Thyroiditis
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the pathological pattern, characteristic features, treatment, complications and prognosis of Hashimoto's thyroiditis in upper Egypt.


Eligibility criteria: Inclusion Criteria:

* All patients with Hashimoto's thyroiditis, males or females, any age, at upper egypt .

Exclusion Criteria:

* Patients with associated other thyroid pathology other than Hashimoto's thyroiditis.

Primary outcomes:
measure: Early post operative follow up of Hashimoto's thyroiditis
timeFrame: 3 days after the operation
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospital
city: Sohag
country: Egypt
facility: Sohag university hospital
Study officials:
References:
citation: Feldt-Rasmussen U. Hashimoto's thyroiditis as a risk factor for thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 2020 Oct;27(5):364-371. doi: 10.1097/MED.0000000000000570.
citation: Cipolla C, Sandonato L, Graceffa G, Fricano S, Torcivia A, Vieni S, Latteri S, Latteri MA. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg. 2005 Oct;71(10):874-8.
citation: Kashima K, Yokoyama S, Noguchi S, Murakami N, Yamashita H, Watanabe S, Uchino S, Toda M, Sasaki A, Daa T, Nakayama I. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid. 1998 Mar;8(3):197-202. doi: 10.1089/thy.1998.8.197.
Clinical trial NCT06655415: Family Members At INcreased-risk for Developing Inflammatory Bowel Disease
Official title: Family Members At INcreased-risk for Developing Inflammatory Bowel Disease (FIND-IBD)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Inflammatory Bowel Disease (IBD)
Ulcerative Colitis (UC)
IBD-unclassified (IBD-U)
Indeterminate Colitis
Crohn's Disease Colon
Crohn's Colitis
Crohn's Ileocolitis
Crohn's Gastritis
Crohn's Jejunitis
Crohn's Duodenitis
Crohn's Esophagitis
Ulcerative Proctitis
Ulcerative Proctosigmoiditis
Keywords: Inflammatory Bowel Disease
IBD
Ulcerative colitis
Crohn's disease
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2024-10-23
Enrollment: 50
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: First-degree relatives (FDRs) of those with IBD.

Brief summary: First-degree relatives of people with inflammatory bowel disease ("IBD," including Crohn's disease and ulcerative colitis) have an increased risk for developing IBD themselves. This study will follow unaffected first-degree relatives (who do not have IBD) over time to understand if their behaviors, diet, and biomarkers for IBD can help predict who gets IBD and if IBD can be prevented in these high-risk individuals. Participants will be asked once per year to complete a questionnaire and have their blood, stool, and urine collected. The anticipated length of the study (registry) is approximately 10 years or longer. Parts of this study, such as the questionnaires and stool and urine collection, may be done from home, while other parts, such as the blood draw, will need to be done from Massachusetts General Hospital.


Eligibility criteria: Inclusion Criteria:

* Ability to give informed consent
* Ability to complete all study visits and study-related procedures
* Ability to understand and complete study questionnaires
* Must have at least one first-degree relative with inflammatory bowel disease (Crohn's disease, ulcerative colitis, or IBD-unclassified)
* Age ≥ 14

Exclusion Criteria:

* Individuals with existing diagnoses of inflammatory bowel disease (ulcerative colitis, Crohn's disease, or IBD-unclassified)
* Evidence of clinical signs or symptoms of IBD, which will be identified on pre-screening interview with the study coordinator.

Primary outcomes:
measure: Number of participants who develop inflammatory bowel disease
timeFrame: Through study completion (an anticipated 10 years)
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Emily W Lopes, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03527615: Clinical Pharmacist Anticoagulant Stewardship
Official title: Clinical Pharmacist Led Hospital-Wide Direct Oral Anticoagulant Stewardship Program
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Safety Issues
Anticoagulant Toxicity
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2018-05-17
Enrollment: 4000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients hospitalized in Hadassah Medical Center with a physician's order for direct oral anticoagulants.

Brief summary: Initiative to improve direct anticoagulant utilization involving programmatic review by clinical pharmacists in collaboration with multidisciplinary team.

Detailed description: The Hadassah Hebrew University Medical Centers' Clinical Pharmacy team initiated a hospital-wide program, in collaboration with the institutions' coagulation specialists, including two hematologists and a clinical pharmacologist, for monitoring and promoting safe and effective prescription of direct oral anticoagulants (DOAC) during hospitalization. Electronic medical records throughout the hospital are screened for DOAC orders. All DOAC orders are assessed by a clinical pharmacist for potentially-inappropriate prescribing. When potentially-inappropriate prescribing or a drug-related problem is identified, the clinical pharmacist provided consultation on management options. In specific cases, additional guidance is provided by coagulation specialists. Consultations are recorded in the electronic medical record. Performance measures are collected and summarized.

Eligibility criteria: Inclusion Criteria:

Patients hospitalized in Hadassah Medical Center with a physician's order for direct oral anticoagulants (apixaban, rivaroxaban, or dabigatran).

Exclusion Criteria:

Patients hospitalized in departments without computerized physician order entry.

Primary outcomes:
measure: Percent of clinical pharmacist consultations accepted by attending physician.
timeFrame: At forty-eight months
Secondary outcomes:
measure: Percent of clinical pharmacist consultations accepted by attending physician.
timeFrame: At six months
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization, Jerusalem, Israel
Study officials:
affiliation: Hadassah University Medical Center
name: Mordechai Muszkat, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Perlman A, Horwitz E, Hirsh-Raccah B, Aldouby-Bier G, Fisher Negev T, Hochberg-Klein S, Kalish Y, Muszkat M. Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. Isr J Health Policy Res. 2019 Feb 1;8(1):19. doi: 10.1186/s13584-019-0285-9.
Clinical trial NCT01004315: A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder
Official title: A Randomized, Double Blind, Placebo Controlled, Phase III Study of KUC-7483 in Patients With Overactive Bladder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Overactive Bladder
Keywords: Overactive bladder
Frequency
Micturition
Urgency
Urge urinary incontinence
OAB
Lead sponsor: Kissei Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2009-10-29
Enrollment: 750
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and the safety of KUC-7483 in overactive bladder patients.


Eligibility criteria: Inclusion Criteria:

* Patients with a symptom of overactive bladder for more than 6 months.
* Patients who meet the following condition during the 3-day bladder diary period.

  * the mean number of micturitions per 24 hours is ≥8 times
  * the mean number of urgency episodes per 24 hours is ≥1 time

Exclusion Criteria:

* Patients who are diagnosed as stress urinary incontinence are predominant.
* Patients with urinary calculus, interstitial cystitis, or clinically significant urinary tract infection.

Primary outcomes:
measure: Change from baseline in the mean number of micturitions per 24 hours
timeFrame: 12 weeks
Secondary outcomes:
measure: Change from baseline in the mean number of urgency episodes per 24 hours
timeFrame: 12 weeks
measure: Change from baseline in the mean number of incontinence episodes per 24 hours
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Hokkaido,Tohoku,Kanto,Chubu,Kansai,Shikoku,Kyushu
country: Japan
facility: Japan
Study officials:
affiliation: Clinical Development Department, Kissei pharmaceutical Co., Ltd.
name: Yasuhiro Omori
role: STUDY_DIRECTOR
References:
Clinical trial NCT05428215: Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients
Official title: Comparison of Pharmacokinetics of 17-Beta-Estradiol Via Oral Administration With Sublingual Placement Versus Oral Administration With Swallowing of 17-Beta-estradiol in Male-to-Female Transgender Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Gender Dysphoria
Keywords: estradiol
gender-affirming estrogen
Lead sponsor: MaineHealth
Sponsor class: OTHER
First posted: 2022-06-23
Enrollment: 2
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Each subject will take their individualized dose of 17B-estradiol tablet orally for 2 weeks and sublingually for 2 weeks. The subject will then take their same dose of 17B-estradiol via the other means of administration for 2 weeks. The order in which this occurs will be randomized.
Primary purpose: TREATMENT

Brief summary: This crossover study will investigate the pharmacokinetics of oral versus sublingual administration of 17-beta-estradiol in the trans-female population.


Eligibility criteria: Inclusion Criteria:

* English speaker
* Currently taking 17-beta-estradiol tablet daily via sublingual or oral route on dose therapeutic for gender-affirming therapy; steady dose for at least 4 weeks
* Serum estradiol and testosterone levels within target therapeutic range (75-200 pg/mL and \<55 ng/dL, respectively)

Exclusion Criteria:

* Active or history of deep venous thrombosis/pulmonary embolism
* Active or recent (within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction)
* Liver dysfunction
* History of breast cancer
* History of orchiectomy
* Known sensitivity or allergy to any components of the study medication
* Taking potent CYP3A4 inhibitors or inducers

Primary outcomes:
measure: Estradiol absorption
timeFrame: Over 24 hours
Secondary outcomes:
measure: Peak serum estradiol
timeFrame: Peak over 24 hour period
measure: Serum estradiol Nadir
timeFrame: 24 hours from last estradiol administration
measure: Suppression of Testosterone
timeFrame: 24 hours from last estradiol administration on Study Day 14 and 28
measure: Serum estrone to estradiol ratio
timeFrame: Hours from administration of estradiol: 0, 1, 2, 4, 6, and 8 hours
measure: Sex hormone binding globulin
timeFrame: 0 hours from estradiol administration on Study Day 14 and 28
Other outcomes:
Locations:
city: Portland
country: United States
facility: Maine Medical Center
state: Maine
Study officials:
affiliation: MaineHealth
name: Katherine Davis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01095315: Delayed Positioning in Cesarean Section
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypotension
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2010-03-30
Enrollment: 86
Sex: FEMALE
Minimum age (years): 28
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Maternal hypotension is a common problem during cesarian section under spinal anesthesia. The possible explanation for this is combined aortocaval compression by gravid uterus in parturient in addition to reduced systemic vascular resistance by spinal anesthesia. The investigators evaluated if the incidence of hypotension would be decreased by delayed supine positioning, by maintaining lateral position for 6 min after spinal injection, in patients undergoing elective cesarean section.


Eligibility criteria: Inclusion Criteria:

* singleton parturients undergoing elective cesarean section
* gestational age over 37 weeks

Exclusion Criteria:

* pregnancy with hypotension
* expecting fetal depression

Primary outcomes:
measure: hypotension
timeFrame: after intrathecal injection until delivery (for 20 minutes)
Secondary outcomes:
measure: sensory block level
timeFrame: during cesarean section
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06968715: Hydrogen-Rich Water and Metabolic Health in Adults: A 12-Week Randomized Trial
Official title: The Effects of 12-week Hydrogen-rich Water Consumption on Body Composition and Metabolic Biomarkers in Adults With Metabolic Syndrome and Varying Breath Hydrogen Levels
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Metabolic Syndrome
Lead sponsor: University of Novi Sad, Faculty of Sport and Physical Education
Sponsor class: OTHER
First posted: 2025-05-13
Enrollment: 40
Sex: ALL
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The HYDRO-RESPOND trial is a 12-week randomized controlled study investigating the effects of daily hydrogen-rich water (HRW) consumption on body composition and metabolic biomarkers in adults diagnosed with metabolic syndrome. The study also explores whether individual differences in baseline breath hydrogen levels influence response to HRW. Participants are randomly assigned to receive either HRW or a placebo, with outcomes including changes in body fat, waist circumference, glucose metabolism, lipid profiles, and inflammatory markers. The trial aims to determine the therapeutic potential of HRW and identify predictors of individual responsiveness.


Eligibility criteria: Inclusion Criteria:

* Age 30-65 years
* Metabolic syndrome (NHS) (at least 3 of the 5 following criteria):

  * Waist circumference of ≥ 102 cm in men and ≥ 88 cm in women
  * Hypertriglyceridemia (≥ 1.695 mmol/L)
  * Low HDL-C (\< 1.04 mmol/dL in men and \< 1.30 mmol/dL in women)
  * High blood pressure (\> 130/85 mmHg)
  * High fasting glucose (\> 6.1 mmol/L)
* Not physically active
* Informed consent signed

Exclusion Criteria:

* Major chronic disease and acute injuries
* History of dietary supplement use during the past 4 weeks
* History of metabolism-modulating pharmaceuticals use during the past 4 weeks
* No consent to randomization
* Participation in other studies

Primary outcomes:
measure: Waist circumference
timeFrame: Change from baseline waist circumference at 12 weeks
Secondary outcomes:
measure: Body fat
timeFrame: Change from baseline body fat at 12 weeks
measure: Lipoprotein (a)
timeFrame: Change from baseline lipoprotein (a) at 12 weeks
measure: Total antioxidant capacity
timeFrame: Change from baseline total antioxidant capacity at 12 weeks
Other outcomes:
Locations:
city: Novi Sad
country: Serbia
facility: Applied Bioenergetics Lab at Faculty of Sport and PE
state: Vojvodina
Study officials:
References: